IL-1β Receptor antagonist reduces inflammation in hemodialysis patients

Journal of the American Society of Nephrology

Volumn 22, Issue 3, 2011, Pages 437-442

  Hung, Adriana M ^a,b   Ellis, Charles D ^b   Shintani, Ayumi ^b   Booker, Cindy ^b   Ikizler, T Alp ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; INTERLEUKIN 6; PLACEBO; PREALBUMIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ADULT; ARTICLE; ASTHMA; CLINICAL ARTICLE; CYTOKINE PRODUCTION; DISEASE CONTROL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FATIGUE; FEMALE; HEMATOMA; HEMODIALYSIS PATIENT; HUMAN; INFECTION; INFLAMMATION; INJECTION SITE REACTION; MALE; NUTRITION; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOFT TISSUE INFECTION; THROMBOCYTOPENIA;

EID: 79952336504     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2010070760     Document Type: Article

References (39)

1. Collins AJ, Foley RN, Herzog C, Chavers BM, Gilbertson D, Ishani A, Kasiske BL, Liu J, Mau LW, McBean M, Murray A, St Peter W, Guo H, Li Q, Li S, Peng Y, Qiu Y, Roberts T, Skeans M, Snyder J, Solid C, Wang C, Weinhandl E, Zaun D, Arko C, Chen SC, Dalleska F, Daniels F, Dunning S, Ebben J, Frazier E, Hanzlik C, Johnson R, Sheets D, Wang X, Forrest B, Constantini E, Everson S, Eggers PW, Agodoa L: Excerpts from the US Renal Data System 2009 Annual Data Report. Am J Kidney Dis 55: S1-S420, 2010
2. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, Ritz E: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353: 238-248, 2005 (Pubitemid 41058323)
3. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339: 584-590, 1998 (Pubitemid 28385655)
4. Cano NJ, Fouque D, Roth H, Aparicio M, Azar R, Canaud B, Chauveau P, Combe C, Laville M, Leverve XM: Intradialytic parenteral nutrition does not improve survival in malnourished hemodialysis patients: A 2-year multicenter, prospective, randomized study. J Am Soc Nephrol 18: 2583-2591, 2007 (Pubitemid 47378875)
5. Jamison RL, Hartigan P, Kaufman JS, Goldfarb DS, Warren SR, Guarino PD, Gaziano JM: Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: A randomized controlled trial. JAMA 298: 1163-1170, 2007 (Pubitemid 47403102)
6. Suki WN, Zabaneh R, Cangiano JL, Reed J, Fischer D, Garrett L, Ling BN, Chasan-Taber S, Dillon MA, Blair AT, Burke SK: Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 72: 1130-1137, 2007 (Pubitemid 47609037)
7. Hung A, Pupim L, Yu C, Shintani A, Siew E, Ayus C, Hakim RM, Ikizler TA: Determinants of C-reactive protein in chronic hemodialysis patients: Relevance of dialysis catheter utilization. Hemodial Int 12: 236-243, 2008 (Pubitemid 351494279)
8. Ikizler TA, Wingard RL, Harvell J, Shyr Y, Hakim RM: Association of morbidity with markers of nutrition and inflammation in chronic hemodialysis patients: A prospective study. Kidney Int 55: 1945-1951, 1999
9. Stenvinkel P, Wanner C, Metzger T, Heimburger O, Mallamaci F, Tripepi G, Malatino L, Zoccali C: Inflammation and outcome in end-stage renal failure: Does female gender constitute a survival advantage? Kidney Int 62: 1791-1798, 2002 (Pubitemid 35286288)
10. Yeun JY, Levine RA, Mantadilok V, Kaysen GA: C-Reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 35: 469-476, 2000 (Pubitemid 30124077)
11. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C: Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 55: 648-658, 1999 (Pubitemid 29082891)
12. Caglar K, Peng Y, Pupim LB, Flakoll PJ, Levenhagen D, Hakim RM, Ikizler TA: Inflammatory signals associated with hemodialysis. Kidney Int 62: 1408-1416, 2002
13. Arizono K, Nomura K, Motoyama T, Matsushita Y, Matsuoka K, Miyazu R, Takeshita H, Fukui H: Use of ultrapure dialysate in reduction of chronic inflammation during hemodialysis. Blood Purif 22[Suppl 2]: 26-29, 2004
14. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM: The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 62: 1524-1538, 2002 (Pubitemid 35286260)
15. Stenvinkel P, Alvestrand A: Inflammation in end-stage renal disease: Sources, consequences, and therapy. Semin Dial 15: 329-337, 2002
16. Hung AM, Ikizler TA: Hemodialysis central venous catheters as a source of inflammation and its implications. Semin Dial 21: 401-404, 2008
17. Carrero JJ, Stenvinkel P: Persistent inflammation as a catalyst for other risk factors in chronic kidney disease: A hypothesis proposal. Clin J Am Soc Nephrol [4 Suppl 1]: S49-S55, 2009
18. Tripepi G, Mallamaci F, Zoccali C: Inflammation markers, adhesion molecules, and allcause and cardiovascular mortality in patients with ESRD: Searching for the best risk marker by multivariate modeling. J Am Soc Nephrol [16 Suppl 1]: S83-S88, 2005 (Pubitemid 41725091)
19. Weiss G, Goodnough LT: Anemia of chronic disease. N Engl J Med 352: 1011-1023, 2005
20. Macdougall IC, Cooper AC: Erythropoietin resistance: The role of inflammation and pro-inflammatory cytokines. Nephrol Dial Transplant [17 Suppl 11]: 39-43, 2002 (Pubitemid 35277063)
21. Don BR, Kim K, Li J, Dwyer T, Alexander F, Kaysen GA: The effect of etanercept on suppression of the systemic inflammatory response in chronic hemodialysis patients. Clin Nephrol 73: 431-438, 2010
22. Descamps-Latscha B, Herbelin A, Nguyen AT, Roux-Lombard P, Zingraff J, Moynot A, Verger C, Dahmane D, de Groote D, Jungers P, et al.: Balance between IL-1 beta, TNF-alpha, and their specific inhibitors in chronic renal failure and maintenance dialysis. Relationships with activation markers of T cells, B cells, and monocytes. J Immunol 154: 882-892, 1995
23. Dinarello CA, Koch KM, Shaldon S: Interleukin-1 and its relevance in patients treated with hemodialysis. Kidney Int Suppl 24: S21-S26, 1988 (Pubitemid 18078128)
24. Kimmel PL, Phillips TM, Simmens SJ, Peterson RA, Weihs KL, Alleyne S, Cruz I, Yanovski JA, Veis JH: Immunologic function and survival in hemodialysis patients. Kidney Int 54: 236-244, 1998 (Pubitemid 28288040)
25. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J: Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440: 237-241, 2006 (Pubitemid 43372104)
26. Larsen CM, Faulenbach M, Vaag A, Volund A, Ehses JA, Seifert B, Mandrup-Poulsen T, Donath MY: Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 356: 1517-1526, 2007 (Pubitemid 46588416)
27. Biolo G, Ciocchi B, Bosutti A, Situlin R, Toigo G, Guarnieri G: Pentoxifylline acutely reduces protein catabolism in chronically uremic patients. Am J Kidney Dis 40: 1162-1172, 2002 (Pubitemid 35403127)
28. Castaneda C, Gordon PL, Parker RC, Uhlin KL, Roubenoff R, Levey AS: Resistance training to reduce the malnutrition-inflammation complex syndrome of chronic kidney disease. Am J Kidney Dis 43: 607-616, 2004 (Pubitemid 38401875)
29. Himmelfarb J, Phinney S, Ikizler TA, Kane J, McMonagle E, Miller G: Gamma-tocopherol and docosahexaenoic acid decrease inflammation in dialysis patients. J Renal Nutr 17: 296-304, 2007 (Pubitemid 47284905)
30. Stenvinkel P, Andersson P, Wang T, Lindholm B, Bergstrom J, Palmblad J, Heimburger O, Cederholm T: Do ACE-inhibitors suppress tumour necrosis factor-alpha production in advanced chronic renal failure? J Intern Med 246: 503-507, 1999 (Pubitemid 29529792)
31. Stenvinkel P, Rodriguez-Ayala E, Massy ZA, Qureshi AR, Barany P, Fellstrom B, Heimburger O, Lindholm B, Alvestrand A: Statin treatment and diabetes affect myeloperoxidase activity in maintenance hemodialysis patients. Clin J Am Soc Nephrol 1: 281-287, 2006
32. Dinarello CA: Interleukin-1beta and the autoinflammatory diseases. N Engl J Med 360: 2467-2470, 2009
33. Pai JK, Pischon T, Ma J, Manson JE, Hankinson SE, Joshipura K, Curhan GC, Rifai N, Cannuscio CC, Stampfer MJ, Rimm EB: Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 351: 2599-2610, 2004 (Pubitemid 39628581)
34. Abbate A, Van Tassell BW, Seropian IM, Toldo S, Robati R, Varma A, Salloum FN, Smithson L, Dinarello CA: Interleukin-1beta modulation using a genetically engineered antibody prevents adverse cardiac remodelling following acute myocardial infarction in the mouse. Eur J Heart Fail 12: 319-322, 2010
35. Acharyya S, Ladner KJ, Nelsen LL, Damrauer J, Reiser PJ, Swoap S, Guttridge DC: Cancer cachexia is regulated by selective targeting of skeletal muscle gene products. J Clin Invest, 114: 370-378, 2004 (Pubitemid 39071609)
36. Fouque D, Kalantar-Zadeh K, Kopple J, Cano N, Chauveau P, Cuppari L, Franch H, Guarnieri G, Ikizler TA, Kaysen G, Lindholm B, Massy Z, Mitch W, Pineda E, Stenvinkel P, Trevino-Becerra A, Wanner C: A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int 73: 391-398, 2008 (Pubitemid 351186278)
37. Frison L, Pocock SJ: Repeated measures in clinical trials: Analysis using mean summary statistics and its implications for design. Stat Med 11: 1685-1704, 1992
38. Senn, S: Statistical Issues in Drug Development, Chichester, England, John Wiley & Sons, 2007
39. Vickers AJ: Parametric versus non-parametric statistics in the analysis of randomized trials with non-normally distributed data. BMC Med Res Methodol 5: 35, 2005